9 December 2020 - positive trial results
The company has announced that independent research from The University of Texas has confirmed that the company's Parsortix cell-separation system can capture a single cancer cell in a blood sample for analysis. This analysis will provide information that could be highly advantageous in clinical decision making. The company continues to make progress with the Parsortix technology and although this may seem slow ultimately there could be significant rewards for shareholders. The shares have tended to trade in a range of 40p to 80p over the last few years and buying towards the . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.